Acorah Software Products - Accounts Production 16.5.460 false true 31 December 2023 1 January 2023 false 1 January 2024 31 December 2024 31 December 2024 10347510 Dr Simon Galbraith iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 10347510 2023-12-31 10347510 2024-12-31 10347510 2024-01-01 2024-12-31 10347510 frs-core:CurrentFinancialInstruments 2024-12-31 10347510 frs-core:ComputerEquipment 2024-12-31 10347510 frs-core:ComputerEquipment 2024-01-01 2024-12-31 10347510 frs-core:ComputerEquipment 2023-12-31 10347510 frs-core:SharePremium 2024-12-31 10347510 frs-core:ShareCapital 2024-12-31 10347510 frs-core:RetainedEarningsAccumulatedLosses 2024-12-31 10347510 frs-bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 10347510 frs-bus:FilletedAccounts 2024-01-01 2024-12-31 10347510 frs-bus:SmallEntities 2024-01-01 2024-12-31 10347510 frs-bus:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 10347510 frs-bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 10347510 frs-core:CostValuation 2023-12-31 10347510 frs-core:AdditionsToInvestments 2024-12-31 10347510 frs-core:DisposalsRepaymentsInvestments 2024-12-31 10347510 frs-core:RevaluationsIncreaseDecreaseInInvestments 2024-12-31 10347510 frs-core:CostValuation 2024-12-31 10347510 frs-core:ProvisionsForImpairmentInvestments 2023-12-31 10347510 frs-core:ImpairmentLossProvisionsForImpairmentInvestments 2024-12-31 10347510 frs-core:ImpairmentReversalProvisionsForImpairmentInvestments 2024-12-31 10347510 frs-core:ProvisionsForImpairmentInvestments 2024-12-31 10347510 frs-core:UnlistedNon-exchangeTraded 2024-12-31 10347510 frs-core:UnlistedNon-exchangeTraded 2023-12-31 10347510 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2023-12-31 10347510 frs-core:AdditionsToInvestments frs-core:UnlistedNon-exchangeTraded 2024-12-31 10347510 frs-core:DisposalsRepaymentsInvestments frs-core:UnlistedNon-exchangeTraded 2024-12-31 10347510 frs-core:RevaluationsIncreaseDecreaseInInvestments frs-core:UnlistedNon-exchangeTraded 2024-12-31 10347510 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2024-12-31 10347510 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2023-12-31 10347510 frs-core:ImpairmentLossProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2024-12-31 10347510 frs-core:ImpairmentReversalProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2024-12-31 10347510 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2024-12-31 10347510 frs-bus:Director1 2024-01-01 2024-12-31 10347510 frs-bus:Director1 2023-12-31 10347510 frs-bus:Director1 2024-12-31 10347510 frs-core:CurrentFinancialInstruments 1 2024-12-31 10347510 frs-countries:EnglandWales 2024-01-01 2024-12-31 10347510 2022-12-31 10347510 2023-12-31 10347510 2023-01-01 2023-12-31 10347510 frs-core:CurrentFinancialInstruments 2023-12-31 10347510 frs-core:SharePremium 2023-12-31 10347510 frs-core:ShareCapital 2023-12-31 10347510 frs-core:RetainedEarningsAccumulatedLosses 2023-12-31 10347510 frs-core:CurrentFinancialInstruments 1 2023-12-31
Registered number: 10347510
Cade Hill Investments Limited
Unaudited Financial Statements
For The Year Ended 31 December 2024
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—6
Page 1
Balance Sheet
Registered number: 10347510
2024 2023
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 4 167 330
Investments 5 23,497,641 63,770,685
23,497,808 63,771,015
CURRENT ASSETS
Debtors 6 44,026,230 94,410
Cash at bank and in hand 6,992,087 850,300
51,018,317 944,710
Creditors: Amounts Falling Due Within One Year 7 (7,386,755 ) (15,728 )
NET CURRENT ASSETS (LIABILITIES) 43,631,562 928,982
TOTAL ASSETS LESS CURRENT LIABILITIES 67,129,370 64,699,997
NET ASSETS 67,129,370 64,699,997
CAPITAL AND RESERVES
Called up share capital 8 17,110 17,110
Share premium account 1,206,795 1,206,795
Profit and Loss Account 65,905,465 63,476,092
SHAREHOLDERS' FUNDS 67,129,370 64,699,997
Page 1
Page 2
For the year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Dr Simon Galbraith
Director
29/09/2025
The notes on pages 3 to 6 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Cade Hill Investments Limited is a private company, limited by shares, incorporated in England & Wales, registered number 10347510 . The registered office is Unit 5, Avenue Business Park, Brockley Road, Elsworth, Cambridge, CB23 4EY.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Computer Equipment 3 years straight line
2.3. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
2.4. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.
Page 3
Page 4
2.5. Investments
Investments in equity instruments are measured initially at fair value, which is normally the transaction price. Transaction costs are excluded if the investments are subsequently measured at fair value through profit and loss. Subsequent to initial recognition investments that can be measured reliably are measured at fair value with changes recognised in the profit and loss. 
Where there is no readily ascertainable market value investments are recorded at cost less any provision for impairment.
3. Average Number of Employees
Average number of employees, including directors, during the year was: NIL (2023: NIL)
- -
4. Tangible Assets
Computer Equipment
£
Cost
As at 1 January 2024 493
As at 31 December 2024 493
Depreciation
As at 1 January 2024 163
Provided during the period 163
As at 31 December 2024 326
Net Book Value
As at 31 December 2024 167
As at 1 January 2024 330
5. Investments
Subsidiaries Associates Unlisted Other Total
£ £ £ £ £
Cost
As at 1 January 2024 100 19,144,255 970,491 45,439,605 65,554,451
Additions - 25 100,000 - 100,025
Disposals - - - (43,573,360 ) (43,573,360 )
Revaluations - - - 3,374,839 3,374,839
As at 31 December 2024 100 19,144,280 1,070,491 5,241,084 25,455,955
Provision
As at 1 January 2024 - 1,061,500 722,266 - 1,783,766
Impairment losses 100 55,750 133,698 - 189,548
Reversal of past impairments - (15,000 ) - - (15,000 )
As at 31 December 2024 100 1,102,250 855,964 - 1,958,314
Net Book Value
As at 31 December 2024 - 18,042,030 214,527 5,241,084 23,497,641
As at 1 January 2024 100 18,082,755 248,225 45,439,605 63,770,685
Page 4
Page 5
The company's investments at the Statement of Financial Position date in the share capital of companies include the following:
Associated Companies:
Octopus Deploy Pty. Ltd
Registered Office: Australia
Nature of Business: Development and retail of computer software
Class of Shares: Ordinary
Holding %: 11.13%
Red Gate Software Group Ltd
Registered Office: Cavendish House, Cambridge Business Park, Cambridge, CB4 0XB, United Kingdom
Nature of Business: Development and retail of computer software
Class of Shares: Ordinary A & Ordinary B
Holding %: 5.39%
The Independent Adventure Group Ltd
Registered Office: International House, Holborn Viaduct, London, United Kingdom, EC1A 2BN
Nature of Business: Travel industry
Class of Shares: Ordinary
Holding %: 33.30%
Syskit UK Ltd
Registered Office: Unit 5, Avenue Business Park, Brockley Road, Elsworth, CB23 4EY
Nature of Business: Development and retail of computer software
Class of Shares: Ordinary, A Preference & B Preference
Holding %: 31.80%
BoobyBiome Ltd
Registered Office: Unit 3 21 Portland Rise, London, United Kingdom
Nature of Business: Research and experimental development on biotechnology
Class of Shares: Ordinary
Holding %: 12.36%
Opti Laboratories Ltd
Registered Office: 3 Baird Gardens, Blantyre, Glasgow, United Kingdom, G72 0WT
Nature of Business: Medical
Class of Shares: Ordinary A shares
Holding %: 25%
Production Ready AI
Registered Office: Unit 5, Avenue Business Park, Brockley Road, Elsworth, Cambridge, CB23 4EY
Nature of Business: Software development
Class of Shares: Preference
Holding %: 26.67%
Subsidiaries
Pharmaglow Ltd
Registered Office: Unit 5, Avenue Business Park, Brockley Road, Elsworth, Cambridge, CB23 4EY
Nature of Business: Media
Class of Shares: Ordinary
Holding %: 100%
Unlisted Investments are held at cost less impairment as no market/fair value is available at the Statement of Financial Position date.
Other Investments are Managed Investment funds, at the Statement of Financial Position date the Investments are held at Market Value.
Page 5
Page 6
6. Debtors
2024 2023
£ £
Due within one year
Trade debtors 20,803 3,303
Prepayments and accrued income 2,242 29,727
Other debtors 4,858 6,218
Other loan 21,095 -
VAT 12,275 3,211
Director's loan account 1,003,802 2,051
Amounts owed by group undertakings 42,960,876 -
Amounts owed by subsidiaries 279 49,900
44,026,230 94,410
7. Creditors: Amounts Falling Due Within One Year
2024 2023
£ £
Trade creditors 9,196 -
Other loans 7,323,955 -
Amounts owed to participating interests - 5,020
Other creditors 53,604 10,708
7,386,755 15,728
8. Share Capital
2024 2023
£ £
Allotted, Called up and fully paid 17,110 17,110
9. Directors Advances, Credits and Guarantees
Included within Debtors are the following loans to directors:
As at 1 January 2024 Amounts advanced Amounts repaid Amounts written off As at 31 December 2024
£ £ £ £ £
Dr Simon Galbraith 2,051 1,001,751 - - 1,003,802
An advance of £1,000,000 was made on 6 December 2024. Interest is charged at HM Revenue and Customs official rate of interest. The loan, together with any accrued interest, was cleared on 3 September 2025.
10. Related Party Transactions
Pharmaglow LtdPharmaglow Ltd is a wholly owned subsidiary.During the previous year the company provided an interest free, unsecured loan of £49,900 to Pharmaglow Ltd. As at 31 December 2024 £279 remains outstanding and is shown within debtors due within one year. A provision for irrecoverable amounts has been made in 2024 amounting to £28,526.

Pharmaglow Ltd

Pharmaglow Ltd is a wholly owned subsidiary.

During the previous year the company provided an interest free, unsecured loan of £49,900 to Pharmaglow Ltd. As at 31 December 2024 £279 remains outstanding and is shown within debtors due within one year. A provision for irrecoverable amounts has been made in 2024 amounting to £28,526.

Page 6